Clinical Report: Incoming ASRS President Shares Vision for Future
Overview
Dr. Geoffrey G. Emerson, the incoming president of ASRS, emphasizes the importance of inclusion, innovation, and early career engagement to address the challenges facing retina specialists. He highlights the need for training more specialists and the role of new technologies in improving patient care while addressing workforce shortages.
Background
Detail ASRS's support mechanisms and specific technologies that enhance patient care.
Data Highlights
No numerical or trial data available in the article.
Key Findings
- Dr. Emerson aims to increase participation from underrepresented groups in ASRS.
- There is a projected workforce shortage in retina specialists, necessitating increased training efforts.
- New technologies have improved patient care but do not address workforce shortages or healthcare costs.
- ASRS has dedicated sections for fellows in training and early career specialists to foster engagement.
- Mentorship and leadership development are key components of ASRS's strategy for the future.
Clinical Implications
Healthcare professionals should prioritize mentorship and inclusion of early career specialists in leadership roles to ensure the future of retina care. Additionally, there is a need to advocate for training programs that address the anticipated workforce shortage in the field.
Conclusion
Dr. Emerson's vision for ASRS underscores the importance of inclusivity and innovation in addressing current challenges in retina care. By engaging younger professionals and leveraging new technologies, ASRS aims to enhance the future of the specialty.
References
- Ophthalmology Management, 2025 -- A Blueprint for Practice Success
- Ophthalmology Management, 2019 -- EYE ON OOSS
- Ophthalmology Management, 2017 -- Eye on OOSS
- Ophthalmology | Vol 132, Issue 4, 2025 -- ScienceDirect
- The ASCO Post — ASCO Will Change with the Times
- Ophthalmology | Vol 132, Issue 4, Pages A1-A20, P1-P344, e1-e78, 375-506 (April 2025) | ScienceDirect.com by Elsevier
- Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE - PubMed
- Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial - ScienceDirect
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.







